In March 2025, Aberaeneca took an important step by obtaining a biotechnology company Exobiotech specialized in cell therapy for the treatment of cancer. This acquisition will increase the value of $ 1 billion, Astrazenca's oncological pipeline and will increase the ability to cope with increasing challenges in cancer care. The agreement further strengthens the location of AstraZeneca in cancer immunotherapy, as cell therapy appears as a promising limit in the fight against different types of cancer.
In February 2025, Biontech took a ground-breaking step in cancer immunotherapy with a large cylindrical study launch for individual mRNA cancer vaccines in Europe. This growth represents an important milestone in the development of cancer treatment, as the purpose of Biontech is to use the accuracy and adaptability of MRNA technology to create a vaccine that can target personal cancer mutations. By taking advantage of the success of MRNA technology used in COVID-19 vaccines, Biotech is now focusing on using this innovative approach to treat different types of cancer, which marks a significant change for personal medicine in oncology.
In July 2024, Ginkgo bought Biovores Zymergen, a company specializing in bio production to increase its position in industrial biotechnology rooms. This acquisition reflects Ginkgo's strategy to expand its capabilities in synthetic biology and bioboxes, and strengthens its role in changing industries through biotechnology. By bringing Zymengen to the board, Ginkgo aims to improve its technical infrastructure and accelerate the development of new solutions for many white Biotechnology applications, including permanent materials and biobed products.
In March 2024, Novosymes and Carbioce announced a collaboration focusing on handling plastic waste through biotechnology. The two companies work together to develop enzymes that can break PET plastic, an innovation that promises to revolutionize plastic recycling processes. The partnership deals with the growing global plastic waste crisis by recycling pet plastic and making it easy to reduce the environmental impact of plastic pollution.
In June 2023, Fizer took an important step in genetic medicine by receiving a biotechnic start-up focusing on gene therapy against rare diseases. This procurement is part of the broad strategy of the physicist to expand the rapidly growing area of genetic medicine, where gene therapy can provide life-changing treatment for patients with rare genetic disorders. By achieving this biotechnological start-up, Fugger strengthens the ability to bring an innovative gene-based treatment into the market, giving the company a major player in the developed landscape of genetic medicine.
In August 2023, Novo Nordic reported major progress in the development of gene therapy for haemophilia, a bleeding disorder that was difficult to treat for a long time. The company's progress in gene therapy for haemophilia is expected to change the treatment scenario for individuals with this condition, giving them long-term relief and even a treatment ability. Novo Nordisk's research in genetic medicine innovates in the treatment of rare diseases, with the improvement of the patient's results, and takes into account to provision of more individual and effective therapeutic alternatives for people living with chronic conditions such as haemophilia.
Impact of Recent developments in White Biotechnology Industry
This acquisition will significantly bolster AstraZeneca’s oncology pipeline, positioning the company to lead in the burgeoning field of cancer immunotherapy. The integration of EsoBiotec’s cell therapy innovations will enable AstraZeneca to offer more personalized and effective cancer treatments. This development is a strong indicator of the industry's increasing focus on personalized medicine and cell-based therapies, which are expected to revolutionize cancer care by targeting tumors more precisely and with fewer side effects.
The personalized mRNA cancer vaccine trials launched by BioNTech represent a monumental leap in cancer treatment. By utilizing the success of mRNA technology from COVID-19 vaccines, BioNTech is adapting the same approach to target specific mutations in cancer cells. The role of white biotechnology in this breakthrough lies in its ability to harness genetic engineering, biotechnology-driven biomarker identification, and innovative vaccine production methods to develop tailored treatments. This development has the potential to transform oncology by offering vaccines personalized to individual cancer profiles, making treatments more effective and reducing adverse effects.
Ginkgo Bioworks' acquisition of Zymergen strengthens its position in the bio-manufacturing sector and will enhance its capabilities in synthetic biology. This move allows Ginkgo to scale up its production of bio-based materials and sustainable solutions, offering a viable alternative to petroleum-based products. This acquisition highlights the growing importance of white biotechnology in industrial applications, including the production of biodegradable materials and biofuels, which will have a long-term environmental impact.
Novozymes and Carbios’ partnership to develop enzymes capable of breaking down PET plastics has the potential to revolutionize the recycling industry. By improving PET plastic recycling processes, the collaboration could significantly reduce the environmental impact of plastic waste, a growing global concern. The partnership will help transition the industry toward a circular economy by making plastic recycling more efficient and sustainable.
Pfizer’s acquisition of a gene therapy-focused biotech startup demonstrates the pharmaceutical giant’s commitment to expanding its footprint in the rapidly evolving field of genetic medicine. This acquisition reflects the industry's shift toward targeted therapies and personalized medicine, particularly for rare diseases. The development will spur innovation in gene therapies, offering new treatments for conditions that have long lacked effective solutions. With Pfizer’s backing, gene therapies are likely to move closer to widespread clinical use, particularly for diseases that previously had few treatment options, significantly impacting the future landscape of medical care for genetic disorders.
Novo Nordisk’s advancement in gene therapy for haemophilia represents a breakthrough in the treatment of bleeding disorders. By providing potential cures and long-term relief for haemophilia patients, this development could reshape the treatment paradigm for genetic disorders. The success of this gene therapy could pave the way for further key innovations in White Biotechnology, especially for other rare diseases.
Source:
News Outlet: CNN, Reuters, NBC News
Contact Us